Complete androgen blockade versus monotherapie;Komplette androgenblockade versus monotherapie

Urologe - Ausgabe A

Volumn 37, Issue 2, 1998, Pages 149-152

  Altwein, J E ^a  

^a KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

Author keywords

Maximal androgen deprivation; Monotherapy; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; CYPROTERONE ACETATE; FLUTAMIDE; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER PAIN; CLINICAL TRIAL; HUMAN; MALE; META ANALYSIS; PROSTATE CANCER; QUALITY OF LIFE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; MALE; ORCHIECTOMY; PALLIATIVE CARE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 0031920098     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050163     Document Type: Article

References (12)

1. Pavone-Macaluso M, Ferraro G, Serretta V, Micali F, Pisani E (1997) Flutamide alone versus total androgen blockade in advanced carcinoma of the prostate: long-term results of a multicenter trial. Br J Urol 80 [Suppl 2]: 278 A
2. Crawford ED, Eisenberg MA, McLeod DG, Spalding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424
3. Eisenberger M, Crawford ED, McLeod D, Loehrer P, Wilding G, Blumenstein B (1997) A comparison of bilateral orchiectomy (orch) with or without flutamide in stage D2 prostate cancer (NCI INT-0105 SWOG/ECOG). Proc Am Soc Clin Oncol 16: 2A
4. Denis JL, Whelan P, Carneiro de Moura JL, Newling D (1993) Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42: 119-130
5. Debruyne FMJ, de Géry A, Hucher M, Godfroid N, Witjes WPJ (1997) Nilutamide combined with orchiectomy in advanced prostate cancer: an updated meta-analysis of 7 randomized, placebo-controlled trials. Br J Urol 80 [Suppl 2]: 277A
6. Janknegt RA, Crawford ED, for The International Anandron study Group (1993) Long-term efficacy and safety of maximal androgen blockade (MAB) with nilutamide (anandron) and castration in stage D2 prostate cancer. J Urol 149: 77-83
7. Smith JA Jr, Janknegt RA, Abbou CC, de Gery A (1997) Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate. Eur Urol [Suppl 3]: 25-29
8. Dijkman GA, Janknegt RA, Reijke TM, Debruyne FMJ, Anandron Study Group (1997) Long-term efficacy and safety of nilutamide penis castration in advanced prostate cancer and the significance of early PSA normalization. J Urol 158: 160-163
9. Altwein JE (1997) Maximale Androgenblokkade: Metaanalyse und kein Ende. Akt Urol 28: 129-132
10. Caubert JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Erustoff MS, Ross SD (1997) Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using monsteroidal antiandrogens. Urology 49: 71-78
11. Prostate Cancer Trialists' Collaborative Group (1995) Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346: 265-269
12. Crawford ED, Smith JA, Soloway MS (1990) A randomized controlled trial of leuprolide and androgen versus leuprolide and placebo in advanced prostate cancer. J Urol 143: 221 A